Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 16/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 15/20 | 0.49 |
| ▸ | CCR2 | P41597 | 2/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14889504 | 0.87 | SLC6A3 (0.61) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL16474237 | 0.87 | SLC6A3 (0.61) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL2471888 | 0.86 | SLC6A3 (0.62) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL19749354 | 0.81 | SLC6A3 (0.42) | SLC6A3SLC6A4CCR2SLC6A2 | |
| SCHEMBL20209823 | 0.78 | SLC6A4 (0.76) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL13273210 | 0.75 | SLC6A4 (0.59) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL20209815 | 0.75 | SLC6A4 (0.59) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL3516287 | 0.72 | SLC6A3 (0.68) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL3520671 | 0.72 | SLC6A3 (0.68) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL3520667 | 0.72 | SLC6A3 (0.68) | SLC6A3SLC6A4SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10428021-B2 | Triple reuptake inhibitors and methods of their use | SUNOVION PHARMACEUTICALS INC. (US) | 2019-10-01 | — | — | US | disclosed |
| US-20180148407-A1 | TRIPLE REUPTAKE INHIBITORS AND METHODS OF THEIR USE | SUNOVION PHARMACEUTICALS INC. | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10428021-B2 | Triple reuptake inhibitors and methods of their use | SLC18A2, SLC6A2, SLC18A3 | SLC6A3 5/4885SLC6A4 4/4885CCR2 4358/4885 |
| US-20180148407-A1 | TRIPLE REUPTAKE INHIBITORS AND METHODS OF THEIR USE | SLC18A2, SLC6A2, SLC18A3 | SLC6A3 5/4885SLC6A4 4/4885CCR2 4358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.